At a glance
- Originator Novartis
- Developer Nonindustrial source; Novartis
- Class Anti-ischaemics; Antidepressants; Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Anxiety disorders in Poland (Unknown route)
- 17 Sep 1997 No-Development-Reported for Epilepsy in Germany (PO)
- 17 Sep 1997 No-Development-Reported for Epilepsy in Switzerland (PO)